AVI CO 004

Drug Profile

AVI CO 004

Alternative Names: AVI-CO-004

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avixgen
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 18 Aug 2017 Ebixen announces intention to submit phase II IND to Korea FDA for HIV-1 infections
  • 18 Aug 2017 Ebixen plans a phase II trial for HIV-1 infections in South Korea (PO)
  • 09 Mar 2017 Avixgen initiates enrolment in a phase I trial In Volunteers in South Korea (KCT0002279)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top